May 9, 2017 | Hong Kong-based investment firm AID Partners Capital Ltd will acquire Israeli medical diagnostic company GeneSort for $23 million. The deal will provide GeneSort with additional resources and support as is seeks to expand into Southeast Asia and other global markets. Moshe Hogeg’s tech focused venture capital firm Singulariteam fund is the largest investor in GeneSort, having invested $2.2 million in the company. GeneSort is a molecular diagnostics company focused on integrating molecular genomics with personalized therapeutic approaches. GeneSort also recently signed a development contract with the government of Malta, and also won a contract with the Israeli government to deploy diagnostic testing in the country.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli Cybersecurity Startup To Provide Training For IDF
October 10, 2024
Johnson & Johnson Completes Purchase Of Israeli Startup V-Wave
October 10, 2024
Weizmann Researchers Create Biodegradable Composite Plastic
October 09, 2024
IIA Funds Further Israeli R&D Into Crustacean Gene Modification
October 09, 2024
Facebook comments